NLRP3 and metabolic dysfunction-associated steatotic liver disease: Aberrant interleukin 1β (IL-1β) production and NLR family pyrin domain containing 3 (NLRP3) inflammasome activation have been shown to elicit dysregulated inflammatory responses in several metabolic diseases, including obesity, type 2 diabetes, hyperglycemia, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD) 1, 2.